EUVIMEDEUVIMED entdecken
Open Access

Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda

Lydia Businge iD, Marc Hagenimana, Melitah Motlhale, Aude Bardot, Biying Liu, Kathryn Anastos iD, Philip E Castle, Gad Murenzi, Kimilu Claire, Daniel Sabushimike, Callixte Cyuzuzo, Gallican Kubwimana und 5 weitere

Pediatric Blood & Cancer · 2024-07 · 71 (7)

DOI: 10.1002/pbc.31020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 26.04.2024. Verfasst von Lydia Businge und 16 weiteren Autor:innen. Beteiligte Einrichtung: Rwanda Biomedical Centre (RBC), Kigali, Rwanda. Hauptthemen laut MEDLINE: Neoplasm Staging, Registries, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Vital Strategies, Global Grants Program, Intramural NIH HHS, Bloomberg Philanthropies Data for Health Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The lack of accurate population‐based information on childhood cancer stage and survival in low‐income countries is a barrier to improving childhood cancer outcomes.

Methods

In this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0–14 diagnosed in 2013–2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non‐Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow‐ups to calculate 1‐, 3‐ and 5‐year observed and relative survival by cancer type and stage at diagnosis.

Results

The cohort comprised 412 children, of whom 49% ( n = 202) died within 5 years of diagnosis. Five‐year survival ranged from 28% (95% confidence interval [CI]: 12.5%–45.6%) for BL to 68% (CI: 55%–78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients ( n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3‐year survival was 70% (95% CI: 45.1%–85.3%) and 11.8% (2.0%–31.2%) for limited and advanced non‐HL, respectively ( p < .001).

Conclusion

This study is only the second to report on stage distribution and stage‐specific survival for childhood cancers in sub‐Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low‐resource setting, and highlights the value of population‐based cancer registries in aiding our understanding of the poor outcomes experienced by this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm StagingRegistriesNeoplasmsHumansRwandaMaleChild, PreschoolChildFemaleInfantAdolescentSurvival RateInfant, NewbornFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

Rwandachildhood cancersregistrystagesurvival

Autor:innen und Institutionen

  • Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
  • Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
  • International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
  • African Cancer Registry Network, Prama House, Oxford, UK.
  • Departments of Medicine and of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID-Profile: Lydia Businge, Kathryn Anastos

Förderung

  • Vital Strategies, Global Grants Program
  • Intramural NIH HHS
  • Bloomberg Philanthropies Data for Health Initiative
  • World Health Organization

Zitieren

APA

Businge, L., Hagenimana, M., Motlhale, M., Bardot, A., Liu, B., Anastos, K., Castle, P. E., Murenzi, G., Claire, K., Sabushimike, D., Cyuzuzo, C., Kubwimana, G., Maniragaba, T., Uwinkindi, F., Paczkowski, M., Soerjomataram, I., & Parkin, D. M. (2024). Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda. Pediatric Blood & Cancer, 71(7). https://doi.org/10.1002/pbc.31020

Vancouver

Businge L, Hagenimana M, Motlhale M, Bardot A, Liu B, Anastos K, et al. Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda. Pediatric Blood & Cancer. 2024;71(7). doi:10.1002/pbc.31020

BibTeX
@article{Businge2024,
  author = {Businge, Lydia and Hagenimana, Marc and Motlhale, Melitah and Bardot, Aude and Liu, Biying and Anastos, Kathryn and Castle, Philip E and Murenzi, Gad and Claire, Kimilu and Sabushimike, Daniel and Cyuzuzo, Callixte and Kubwimana, Gallican and Maniragaba, Theoneste and Uwinkindi, Francois and Paczkowski, Maggie and Soerjomataram, Isabelle and Parkin, Donald Maxwell},
  title = {Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {7},
  doi = {10.1002/pbc.31020}
}
Kostenlos starten →